---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-066601"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2026-10-21T11:36:13+00:00"
generated_at: "2026-10-21T11:40:06.425578+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abbott Q3 2026 sales up 14.5% reported, 7.0% comparable; adjusted EPS $1.42; FY guidance tightened to $5.50-$5.55

## Summary
- Total company third-quarter sales were $13.01 billion, up 14.5% reported and 7.0% comparable, with U.S. sales up 28.0% to $5.50 billion.
- GAAP diluted EPS was $0.53 versus adjusted diluted EPS of $1.42; full-year 2026 adjusted EPS guidance reaffirmed at midpoint and narrowed to $5.50-$5.55.
- Diagnostics sales jumped 46.7% reported to $3.31 billion, driven by the March 23, 2026 Exact Sciences acquisition and 13.8% comparable Cancer Diagnostics growth.
- Medical Devices sales rose 6.9% to $5.83 billion, led by 15.0% growth in Electrophysiology; Diabetes Care CGM sales grew 7.3% reported.
- Abbott cited FDA approval of Libre Duo, CE Mark for Amulet 360, FDA approval of TactiFlex Duo and launch of SimpleScreen CRC; Q4 adjusted EPS guided to $1.62-$1.67.

## SEC filing metadata
- accession: 0001628280-26-066601
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2026-10-21T11:36:13+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/0001628280-26-066601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/abt-20261021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-066601
- JSON: https://secwatch.observer/filing/0001628280-26-066601.json
- Plain text: https://secwatch.observer/filing/0001628280-26-066601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.